预约演示
Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions
2024-01-18
临床1期临床申请
Endocanninaboids are naturally occurring endogenous ligands that target cannabinoid receptors.
Credit: Summit Art Creations via Shutterstock.cannabinoid receptors
Swiss coSummit Art Creationspeutics has been given the go-ahead from the European Medicines Agency (EMA) to advance its lead candidate, SYT-510, into a Phase I clinical trial to treat neuropsychiatric disorders.
The first-in-cSynendosibitor targets endocannabinoids—naturally occurringEuropean Medicines Agency (EMA) that help to maintain homeostasSYT-510-510 is said to inhibit endocannabinoid rneuropsychiatric disordersamount of those neurotransmitters available in the synaptic cleft and increases neurotransmission.
In the upcoming planned Phase I first-in-human trial, the focus will be on assessing the safety, tolerability and pharmacokinetics in healthSYT-510nts receiving increasing single doses of SYT-510.
Basel headquartered-Synendos was spun out of the University of Bern in 2019, raising $27.8m in two Series A funding rounds in 2020 and 2021, co-led by Kurma Partners, Sunstone Life ScienceSYT-510es, and Ysios Capital.
The company secured Synendosar Eurostars grant inUniversity of BernUnion (EU) funding scheme, named the EndoCARE programme, to propel preclinical studiKurma Partnersaumatic stress disorder (PTSD) by restoring endocannabinoid balance and exploring early clinical biomarkers.
A GlobalData analyst highlighted that cannabinoid receptors are the most popular target in preclinical development, however using these candidates are controvpost-traumatic stress disorder (PTSD) derived from compounds found in the cannabis plant.
GlobalData is the parent company of Phcannabinoid receptorsgy.cannabinoid-based drugs
While cannabinoid receptors increasePharmaceutical Technologyg the regulatory environment is challenging. At the national level in the US, the largest pharmaceutical market globally, cannabinoids remain illegal under the Controlled Substances Act, despite legalisation allowing medical use in many states.
Medicacannabinoid receptors is permitted in many EU nations, but accessibility is restricted with a special permit granted in specific cases.cannabinoids
In 2018, the UScannabinoidsug Administration (FDA) approved the first anti-epileptic medical marijuana therapy, marketed by GW Pharma which is now part of Jazz Therapeutics, Epidiolex (cannabidiol). Epidiolex generated $736.4m in 2022, according to Jazz Therapeutics’ 2022 annual report. According to GlobalData’s Pharma Intelligence Center, Epidiolex is forecast to generate $1.46bn in 2029.
In the announcemFood and Drug Administration (FDA)ef executive officer of Sepilepticndrea Chicca said: “The transition to a GW Pharmastage company marks a Jazz TherapeuticstoEpidiolex (cannabidiol) SEpidiolexnd for SYT-510, the first candidate in ouJazz TherapeuticsRI molecules.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。